Sumitomo Pharma Co., Ltd. (TYO:4506)
1,345.00
+50.00 (3.86%)
Aug 10, 2026, 3:30 PM JST
Sumitomo Pharma Revenue
Sumitomo Pharma had revenue of 129.50B JPY in the quarter ending June 30, 2026, with 19.90% growth. This brings the company's revenue in the last twelve months to 474.79B, up 14.09% year-over-year. In the fiscal year ending March 31, 2026, Sumitomo Pharma had annual revenue of 453.29B with 13.66% growth.
Revenue (ttm)
474.79B
Revenue Growth
+14.09%
P/S Ratio
1.27
Revenue / Employee
123.90M
Employees
4,980
Market Cap
603.36B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 453.29B | 54.46B | 13.66% |
| Mar 31, 2025 | 398.83B | 84.27B | 26.79% |
| Mar 31, 2024 | 314.56B | -240.99B | -43.38% |
| Mar 31, 2023 | 555.54B | -4.49B | -0.80% |
| Mar 31, 2022 | 560.04B | 44.08B | 8.54% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Eisai | 857.06B |
| Shionogi & | 563.21B |
| Towa Pharmaceutical | 279.94B |
| Sawai Group Holdings | 201.68B |
| Tsumura & Co. | 199.23B |
| Nippon Shinyaku | 180.29B |
| KYORIN Pharmaceutical | 125.68B |
| Mochida Pharmaceutical | 122.04B |
Sumitomo Pharma News
- 4 days ago - Sumitomo Pharma America Earns 2026-2027 Great Place to Work Certification™ - Business Wire
- 10 days ago - Sumitomo Pharma Earnings Call Transcript: Q1 2027 - Transcripts
- 10 days ago - Sumitomo Pharma Quarterly report: Q1 2027 - Filings
- 10 days ago - Sumitomo Pharma Slides: Q1 2027 - Filings
- 11 days ago - Sumitomo Pharma America Announces Enzomenib (DSP-5336) Receives FDA Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia - Business Wire
- 2 months ago - Sumitomo Pharma America Announces Encouraging Clinical and Translational Data at EHA 2026, Highlighting Investigational Combination Therapy in Relapsed/Refractory Myelofibrosis and New Research Findings in Menin Inhibition in Leukemia - Business Wire
- 2 months ago - Sumitomo Pharma America Achieves Key Patient Enrollment Milestone for Pivotal Phase 2 Study of Enzomenib in the Treatment of Relapsed/Refractory Acute Leukemia - Business Wire
- 2 months ago - Sumitomo Pharma America Presents First Clinical Data for SMP-3124LP, an Investigational PEGylated Liposome CHK1 Inhibitor, at ASCO 2026 - Business Wire